Recurrent Ovarian Carcinoma Completed Phase 2 Trials for Bevacizumab (DB00112)

Back to Recurrent Ovarian Carcinoma
IndicationStatusPhase
DBCOND0030000 (Recurrent Ovarian Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01305213Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity CancerTreatment
NCT01010126Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerTreatment
NCT00072566Bevacizumab and Low-Dose Cyclophosphamide in Treating Patients With Recurrent Ovarian Epithelial or Primary Peritoneal CancerTreatment